Selective dihydropyrrolopyrimidine JAK2 inhibitors
US12421238B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 21, 2022 |
| Grant date | Sep 23, 2025 |
| Priority date | — |
| Expiry date | Jul 27, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to the technical field of biomedicine, particularly to a selective dihydropyrrolopyrimidine JAK2 inhibitor or a pharmaceutically acceptable salt thereof. Compared with the prior art, the pyrrolopyrimidine compounds, stereoisomers and pharmaceutically acceptable salts thereof provided by the present invention exhibit better inhibitory activity for Janus Kinase and significantly better selectivity for JAK2 inhibitory targets. In addition, the preferred compounds of the present invention exhibit good pharmacokinetic properties and have the potential to be developed as selective JAK2 inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.